BIODLINK-B(01875) is expected to achieve a operating income of approximately 748 million yuan in 2025.

Dongyang Pharmaceuticals-B (01875) announced that in 2025, it achieved an operating income of approximately 748 million yuan, a year-on-year decrease of 31.93%; a net loss of approximately 100 million yuan, a year-on-year change from profit to loss. In terms of assets and liabilities, the total net assets at the end of 2025 were approximately 626 million yuan, with both current liabilities and non-current liabilities decreasing compared to the previous year.